Table II.
Percentage of iNKT cells with expression of IL-4 or IFN-γ divided according to adverse prognostic factors.
| Variable | ZAP-70-positive patients | ZAP-70-negative patients | P-value |
|---|---|---|---|
| iNKT+IL-4+ (%) | 37.86 (8.00–92.86) | 30.19 (2.36–89.47) | 0.049a |
| iNKT+IFN-γ+ (%) | 22.23 (2.00–68.97) | 25.00 (0.60–83.33) | 0.495 |
| iNKT+IFN-γ+/iNKT+IL-4+ ratio | 0.60 (0.04–2.28) | 0.89 (0.16–3.73) | 0.046a |
| CD38-positive patients | CD38-negative patients | ||
| iNKT+IL-4+ (%) | 36.71 (8.00–92.86) | 33.85 (2.36–89.47) | 0.462 |
| iNKT+IFN-γ+ (%) | 21.43 (5.81–68.97) | 25.55 (0.60–83.33) | 0.382 |
| iNKT+IFN-γ+/iNKT+IL-4+ ratio | 0.57 (0.16–2.68) | 0.77 (0.04–3.73) | 0.176 |
| del(17p13.1) and/or del(11q22.3) | Without del(17p13.1), del(11q22.3) | ||
| iNKT+IL-4+ (%) | 32.13 (12.07–55.56) | 37.71 (2.36–92.86) | 0.548 |
| iNKT+IFN-γ+ (%) | 16.08 (10.53–60.62) | 24.00 (0.60–83.33) | 0.064 |
| iNKT+IFN-γ+/iNKT+IL-4+ ratio | 0.53 (0.32–2.29) | 0.71 (0.04–3.73) | 0.365 |
The P-value was calculated using the Mann-Whitney U test.
a
P<0.05 was considered to indicate a statistically significant difference.